Roche

News

Roche trumpets new glofitamab data in lymphoma at ASCO

Roche will present the new data at next week's ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients with aggressive lymphoma.

News

NICE finds solution to making Keytruda available for TNBC

Around 100 patients in England and Wales with triple negative breast cancer (TNBC) that has spread to other parts of the body could soon access treatment with Merck & Co/MSD's Keytruda,

News

GSK, iTeos take stock after Roche's TIGIT setback

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche'

News

Roche's TIGIT ambitions take another blow

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuste

News

Roche extends Kaiku digital monitoring partnership again

Roche has elevated a longstanding alliance with Finland's Kaiku Health focusing on digital patient monitoring and management (DPMM) to the level of a strategic partnership.

News

CHMP backs Roche's lymphoma bispecific mosunetuzumab

Roche is on the brink of its first regulatory approval for what could be the first bispecific antibody targeting CD3 and CD20 – mosunetuzumab – after getting a positive opinion for the drug

Roche trumpets new glofitamab data in lymphoma at ASCO

NICE finds solution to making Keytruda available for TNBC

GSK, iTeos take stock after Roche's TIGIT setback

Roche's TIGIT ambitions take another blow

Roche extends Kaiku digital monitoring partnership again

CHMP backs Roche's lymphoma bispecific mosunetuzumab

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks